 Neoplasms, Second Primary
"Neoplasms, Second Primary" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
| Descriptor ID |
D016609
|
| MeSH Number(s) |
C04.692
|
| Concept/Terms |
Neoplasms, Second Primary- Neoplasms, Second Primary
- Neoplasm, Second Primary
- Second Primary Neoplasm
- Metachronous Second Primary Neoplasms
- Neoplasms, Metachronous
- Second Primary Neoplasms, Metachronous
- Second Malignancy
- Malignancies, Second
- Malignancy, Second
- Second Malignancies
- Second Neoplasm
- Neoplasm, Second
- Neoplasms, Second
- Second Neoplasms
- Second Primary Neoplasms
- Metachronous Neoplasms
- Metachronous Neoplasm
- Neoplasm, Metachronous
- Neoplasms, Metachronous Second Primary
Neoplasms, Therapy-Associated- Neoplasms, Therapy-Associated
- Neoplasm, Therapy-Associated
- Neoplasms, Therapy Associated
- Therapy-Associated Neoplasm
- Neoplasms, Treatment-Associated
- Neoplasm, Treatment-Associated
- Neoplasms, Treatment Associated
- Treatment-Associated Neoplasm
- Neoplasms, Treatment-Related
- Neoplasm, Treatment-Related
- Neoplasms, Treatment Related
- Treatment-Related Neoplasm
- Therapy-Related Neoplasms
- Therapy Related Neoplasms
- Treatment-Associated Neoplasms
- Treatment Associated Neoplasms
- Treatment-Related Neoplasms
- Treatment Related Neoplasms
- Neoplasms, Therapy-Related
- Neoplasm, Therapy-Related
- Neoplasms, Therapy Related
- Therapy-Related Neoplasm
- Therapy-Associated Neoplasms
- Therapy Associated Neoplasms
Therapy-Associated Cancer- Therapy-Associated Cancer
- Cancer, Therapy-Associated
- Cancers, Therapy-Associated
- Therapy Associated Cancer
- Therapy-Associated Cancers
- Therapy-Related Cancer
- Cancer, Therapy-Related
- Cancers, Therapy-Related
- Therapy Related Cancer
- Therapy-Related Cancers
- Treatment-Related Cancer
- Cancer, Treatment-Related
- Cancers, Treatment-Related
- Treatment Related Cancer
- Treatment-Related Cancers
- Treatment-Associated Cancer
- Cancer, Treatment-Associated
- Cancers, Treatment-Associated
- Treatment Associated Cancer
- Treatment-Associated Cancers
Cancer, Second Primary- Cancer, Second Primary
- Cancers, Second Primary
- Second Primary Cancer
- Second Primary Cancers
- Second Cancer
- Cancer, Second
- Cancers, Second
- Second Cancers
|
Below are MeSH descriptors whose meaning is more general than "Neoplasms, Second Primary".
Below are MeSH descriptors whose meaning is more specific than "Neoplasms, Second Primary".
This graph shows the total number of publications written about "Neoplasms, Second Primary" by people in this website by year, and whether "Neoplasms, Second Primary" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 | | 1996 | 1 | 0 | 1 | | 1997 | 1 | 2 | 3 | | 1998 | 0 | 1 | 1 | | 2001 | 3 | 0 | 3 | | 2002 | 1 | 0 | 1 | | 2006 | 2 | 3 | 5 | | 2007 | 1 | 1 | 2 | | 2008 | 1 | 0 | 1 | | 2009 | 1 | 0 | 1 | | 2011 | 1 | 0 | 1 | | 2012 | 2 | 1 | 3 | | 2013 | 1 | 0 | 1 | | 2014 | 1 | 0 | 1 | | 2015 | 2 | 1 | 3 | | 2016 | 4 | 0 | 4 | | 2017 | 2 | 0 | 2 | | 2019 | 5 | 0 | 5 | | 2020 | 3 | 1 | 4 | | 2021 | 5 | 2 | 7 | | 2022 | 6 | 0 | 6 | | 2023 | 6 | 0 | 6 |
To return to the timeline, click here.
Below are the most recent publications written about "Neoplasms, Second Primary" by people in Profiles.
-
Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, Sokol ES, Frampton G, Soares HP, Puri S, Swami U, Wilky B, Hosein P, Trent J, Lopes GL, Park W, Garrido-Laguna I. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. J Immunother Cancer. 2023 08; 11(8).
-
Im C, Sharafeldin N, Yuan Y, Wang Z, Sapkota Y, Lu Z, Spector LG, Howell RM, Arnold MA, Hudson MM, Ness KK, Robison LL, Bhatia S, Armstrong GT, Neglia JP, Yasui Y, Turcotte LM. Polygenic Risk and Chemotherapy-Related Subsequent Malignancies in Childhood Cancer Survivors: A Childhood Cancer Survivor Study and St Jude Lifetime Cohort Study Report. J Clin Oncol. 2023 09 20; 41(27):4381-4393.
-
Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, de Lima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse C, Badawy SM, Al Hadidi S, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh M, Munshi PN, Nishihori T, Anderson LD, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Impact of second primary malignancy post-autologous transplantation on outcomes of multiple myeloma: a CIBMTR analysis. Blood Adv. 2023 06 27; 7(12):2746-2757.
-
Vaddi PK, Osborne DG, Nicklawsky A, Williams NK, Menon DR, Smith D, Mayer J, Reid A, Domenico J, Nguyen GH, Robinson WA, Ziman M, Gao D, Zhai Z, Fujita M. CTLA4 mRNA is downregulated by miR-155 in regulatory T cells, and reduced blood CTLA4 levels are associated with poor prognosis in metastatic melanoma patients. Front Immunol. 2023; 14:1173035.
-
Tobin RP, Cogswell DT, Cates VM, Davis DM, Borgers JSW, Van Gulick RJ, Katsnelson E, Couts KL, Jordan KR, Gao D, Davila E, Medina TM, Lewis KD, Gonzalez R, McFarland RW, Robinson WA, McCarter MD. Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. Clin Cancer Res. 2023 04 03; 29(7):1209-1219.
-
Reyngold M, Karam SD, Hajj C, Wu AJ, Cuaron J, Lobaugh S, Yorke ED, Dickinson S, Jones B, Vinogradskiy Y, Shukla-Dave A, Do RKG, Sigel C, Zhang Z, Crane CH, Goodman KA. Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2023 09 01; 117(1):53-63.
-
Hamdi OA, Dougherty MI, Rasamny JJ, Greyson MA, Christophel JJ, Shonka DC, Fedder KL, Jameson MJ, Garneau JC. The Clinical Utility and Cost of Routine Staging Exam under Anesthesia for Oral Cavity Squamous Cell Carcinoma. ORL J Otorhinolaryngol Relat Spec. 2023; 85(2):72-79.
-
Wang Y, Kremer LCM, van Leeuwen FE, Armstrong GT, Leisenring W, de Vathaire F, Hudson MM, Kuehni CE, Arnold MA, Haddy N, Demoor-Goldschmidt C, Diallo I, Howell RM, Ehrhardt MJ, Moskowitz CS, Neglia JP, van der Pal HJH, Robison LL, Schaapveld M, Turcotte LM, Waespe N, Ronckers CM, Teepen JC. Cohort profile: Risk and risk factors for female breast cancer after treatment for childhood and adolescent cancer: an internationally pooled cohort. BMJ Open. 2022 11 07; 12(11):e065910.
-
Rosenbaum E, Chugh R, Ryan CW, Agulnik M, Milhem MM, George S, Jones RL, Chmielowski B, Van Tine BA, Tawbi H, Elias AD, Read WL, Budd GT, Qin LX, Rodler ET, Hirman J, Weiden P, Bennett CM, Livingston PO, Ragupathi G, Hansen D, D'Angelo SP, Tap WD, Schwartz GK, Maki RG, Carvajal RD. A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2?and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery. Eur J Cancer. 2022 11; 176:155-163.
-
Li Z, Wu Y, Yates ME, Tasdemir N, Bahreini A, Chen J, Levine KM, Priedigkeit NM, Nasrazadani A, Ali S, Buluwela L, Arnesen S, Gertz J, Richer JK, Troness B, El-Ashry D, Zhang Q, Gerratana L, Zhang Y, Cristofanilli M, Montanez MA, Sundd P, Wallace CT, Watkins SC, Fumagalli C, Guerini-Rocco E, Zhu L, Tseng GC, Wagle N, Carroll JS, Jank P, Denkert C, Karsten MM, Blohmer JU, Park BH, Lucas PC, Atkinson JM, Lee AV, Oesterreich S. Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis. Cancer Res. 2022 04 01; 82(7):1321-1339.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|